Browsing by Author "Ndabambi, Nonkululeko."

Now showing 1 - 5 of 5

Brief report: selection of HIV-1 variants with higher transmission potential by 1% tenofovir gel microbicide.
(Wolters Kluwer Health., 2017) Ngandu, Nobubelo K.; Carlson, Jonathan M.; Chopera, Denis Rutendo.; Ndabambi, Nonkululeko.; Abdool Karim, Quarraisha.; Abdool Karim, Salim Safurdeen.; Williamson, Carolyn.
Abstract available in pdf.
Early evolution of HLA-associated escape mutations in variable Gag proteins predicts CD4+ decline in HIV-1 subtype C infected women.
(Wolters Kluwer Health., 2017) Chopera, Denis Rutendo.; Ntale, Roman.; Ndabambi, Nonkululeko.; Garrett, Nigel Joel.; Gray, Clive M.; Matten, David.; Abdool Karim, Quarraisha.; Abdool Karim, Salim Safurdeen.; Williamson, Carolyn.
Abstract available in pdf.
No evidence for selection of HIV-1 with enhanced gag-protease or nef function among breakthrough infections in the CAPRISA 004 tenofovir microbicide trial.
(2013) Chopera, Denis Rutendo.; Mann, Jaclyn Kelly.; Mwimanzi, Philip.; Omarjee, Saleha.; Kuang, Xiaomei T.; Ndabambi, Nonkululeko.; Goodier, Sarah A.; Martin, Eric.; Naranbhai, Vivek.; Abdool Karim, Salim Safurdeen.; Abdool Karim, Quarraisha.; Brumme, Zabrina L.; Ndung'u, Peter Thumbi.; Williamson, Carolyn.; Brockman, Mark A.
Background: Use of antiretroviral-based microbicides for HIV-1 prophylaxis could introduce a transmission barrier that inadvertently facilitates the selection of fitter viral variants among incident infections. To investigate this, we assessed the in vitro function of gag-protease and nef sequences from participants who acquired HIV-1 during the CAPRISA 004 1% tenofovir microbicide gel trial. Methods and Results: We isolated the earliest available gag-protease and nef gene sequences from 83 individuals and examined their in vitro function using recombinant viral replication capacity assays and surface protein down regulation assays, respectively. No major phylogenetic clustering and no significant differences in gag-protease or nef function were observed in participants who received tenofovir gel versus placebo gel prophylaxis. Conclusion: Results indicate that the partial protective effects of 1% tenofovir gel use in the CAPRISA 004 trial were not offset by selection of transmitted/early HIV-1 variants with enhanced Gag-Protease or Nef fitness.
Replication capacity of viruses from acute infection drives HIV-1 disease progression.
(American Society for Microbiology., 2017) Selhorst, Philippe.; Combrinck, Carina.; Ndabambi, Nonkululeko.; Ismail, Sherazaan D.; Abrahams, Melissa-Rose.; Lacerda, Miguel.; Samsunder, Natasha.; Garrett, Nigel Joel.; Abdool Karim, Quarraisha.; Abdool Karim, Salim Safurdeen.; Williamson, Carolyn.
Abstract available in pdf.
Structure and recognition of a novel HIV-1 gp120-gp41 interface antibody that caused MPER exposure through viral escape.
(Public Library of Science., 2017) Wibmer, Constantinos Kurt.; Gorman, Jason.; Ozorowski, Gabriel.; Bhiman, Jinal N.; Sheward, Daniel J.; Elliott, Debra H.; Rouelle, Julie.; Smira, Ashley.; Joyce, M. Gordon.; Ndabambi, Nonkululeko.; Druz, Aliaksandr.; Asokan, Mangaiarkarasi.; Burton, Dennis R.; Connors, Mark.; Abdool Karim, Salim Safurdeen.; Mascola, John R.; Robinson, James E.; Ward, Andrew B.; Williamson, Carolyn.; Kwong, Peter D.; Morris, Lynn.; Moore, Penelope L.
Abstract available in pdf.